Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403119 | 0.93 | OPRM1 (0.52) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5409573 | 0.91 | OPRM1 (0.50) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5403259 | 0.90 | OPRM1 (0.51) | OPRM1OPRK1OPRD1KCNH2ALDH1A1 | |
| SCHEMBL5403311 | 0.89 | OPRM1 (0.59) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5417254 | 0.88 | OPRM1 (0.46) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5407151 | 0.87 | OPRM1 (0.53) | OPRM1OPRK1OPRD1KCNH2ALDH1A1 | |
| SCHEMBL5403621 | 0.87 | OPRM1 (0.61) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5406251 | 0.86 | CXCR3 (0.47) | OPRM1OPRK1OPRD1CXCR3 | |
| SCHEMBL5398073 | 0.86 | OPRM1 (0.59) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5404536 | 0.85 | HTT (0.51) | OPRM1OPRK1OPRD1KCNH2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1615894-A2 | 3-AZABICYCLO 3.2.1 OCTANE DERIVATIVES | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004089908-A2 | 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRK1 2/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.